Concepedia

David L. Hyslop

DL

Statistics

Publications

6

Citations

416

H-Index

6

Active since

1992

Affiliations

Eli Lilly (United States)(Current)

Medical University of Vienna

Oregon Health & Science University

Keio University

Stanford University

David L. Hyslop is an author at Eli Lilly (United States) specializing in clinical pharmacology, pharmacology, and pharmacotherapy.

Publications per year

1992–2024

6

Publications

6

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Josef S Smolen, Mark C. Genovese, Tsutomu Takeuchi et al. · The Journal of Rheumatology · 2018 · 259 citations · Full text

, , +13

Infections in baricitinib clinical trials for patients with active rheumatoid arthritis

Kevin Winthrop, Masayoshi Harigai, Mark C. Genovese et al. · Annals of the Rheumatic Diseases · 2020 · 93 citations · Full text

, , +14

Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers

Ronald R. Bowsher, Joyce Compton, Jeffrey A. Kirkwood et al. · Antimicrobial Agents and Chemotherapy · 1994 · 22 citations · Full text

, , +12

Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis

David L. Hyslop, Werner Bischoff · The American Journal of Medicine · 1992 · 19 citations

, , +12

THU0166 Safety Profile of Baricitinib in Patients with Active RA: An Integrated Analysis

Josef S Smolen, Mark C. Genovese, Tohru Takeuchi et al. · Annals of the Rheumatic Diseases · 2016 · 13 citations

, , +14

1–5 of 6